Oryzon Genomics, S.A.

Oryzon Genomics, S.A. is a biopharmaceutical company specializing in the development of epigenetics-based therapeutics. The company focuses on creating innovative medicines aimed at treating neurological diseases, oncology, and various other medical conditions. Utilizing its proprietary platform technologies, Oryzon Genomics aims to develop inhibitors that modulate specific epigenetic markers responsible for disease modulation. The company's research efforts include strategic collaborations and partnerships to enhance clinical development and broaden its therapeutic pipeline. Operating within the high-impact biotechnology sector, Oryzon Genomics plays a significant role in advancing medical research by contributing to the understanding and treatment of complex diseases. Headquartered in Spain, the company is an integral part of the European biotechnology landscape and actively participates in global healthcare innovation.